Jeff Bezos backs tiny biotech with $130 mil investment

[Investment House] Below please find a special message from one of our sponsors, Behind the Markets. From time to time we find special opportunities we believe you as a valued customer may want to see. Please note that the following message reflects the opinions and representations of our sponsor alone, and not necessarily the opinion or editorial positions of Investment House, Eagle Financial Publications or Salem Media Group. --------------------------------------------------------------- Dear Fellow Investor, A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda. And they have a clean balance sheet with over $1 billion in cash to fund their efforts. Now, investors are lining up to buy shares. Stock purchases by institutional buyers more than doubled in the last quarter of 2023. What is it about this stock that has everyone excited? [Find out more here ]( "The Buck Stops Here," Dylan Jovine, CEO & Founder Behind the Markets --------------------------------------------------------------- The foregoing is commentary for informational purposes only. All statements and expressions are the opinions of Eagle Products, LLC, or Salem Communications. This information is not meant to be a solicitation or recommendation to buy, sell, or hold securities. We are not licensed or registered in the securities industry. The information presented herein and on the related web site has been obtained from sources believed to be reliable, but its accuracy is not assured. The security portfolios of writers for this issue may, in some instances, include securities mentioned herein and on the related web site. Estimates, assumptions and other forward-looking information are subject to the limits of forecasting. Actual future developments may differ materially due to many factors. No one associated herewith receives compensation in any manner from any of the companies that are discussed in this newsletter or on the related websites. This is a commercial email. It may contain promotion or solicitation. This email was sent to {EMAIL} because you are subscribed to the Carefully Selected Financial Offers from Third Parties List. To unsubscribe please click [here](. To stop receiving emails simply click [here](. View this email in your [web browser](. All Rights Reserved. Investment House - Eagle Products, LLC - a Salem Communications Holding Company, 122 C Street NW, Suite 515, Washington, DC 20001 [Link](